Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Express Scripts CEO sees Amazon as a potential partner: CNBC

Published 11/30/2017, 09:44 AM
Updated 11/30/2017, 09:44 AM
© Reuters. FILE PHOTO - The logo of Amazon is seen at the company logistics center in Lauwin-Planque northern France

(Reuters) - Express Scripts Holding (O:ESRX) sees Amazon.com Inc (O:AMZN), which has been reported to be interested in entering the pharmacy market, as a possible partner rather than a competitor, the chief executive of the pharmacy benefit manager (PBM) said on Thursday on CNBC.

Express Scripts, the biggest PBM in the United States, and drug distributors have been under pressure by the speculated entry of Amazon into the prescription drug market.

"What (Amazon) will see is the magic isn't in lower net prices to consumers," CEO Tim Wentworth said. "It's getting the right drug to consumers and helping them navigate the system." (http://cnb.cx/2nlcc3w)

Wentworth was speaking to CNBC at the Forbes Healthcare Summit conference in New York. He made similar comments last month to analysts.

Last month, Express Scripts said it would "stand well" against any possible competition from Amazon in the pharmacy benefit management business, but added that the company would be a "natural collaborator" for the ecommerce giant.

PBMs negotiate drug benefits for health insurance plans and employers, and have in recent years taken an increasingly aggressive stance in price negotiations with drugmakers.

© Reuters. FILE PHOTO - The logo of Amazon is seen at the company logistics center in Lauwin-Planque northern France

They often extract discounts and after-market rebates from drugmakers in exchange for including their medicines in PBM formularies with low co-payments.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.